Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00416455 · ClinicalTrials.gov registry record · Phase 1
Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 384
- Enrollment target
NCT00416455: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00416455 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 384 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00416455, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 384 participants
- Enrollment target
Study Summary
This phase I/II trial is studying how well fludeoxyglucose F 18 PET scan, CT scan, and ferumoxtran-10 MRI scan finds lymph node metastasis before undergoing chemotherapy and radiation therapy in patients with locally advanced cervical cancer or high-risk endometrial cancer. Diagnostic procedures, such as a fludeoxyglucose F 18 positron emission tomography (PET) scan, computed tomography (CT) scan, and ferumoxtran-10 magnetic resonance imaging (MRI) scan, may help find lymph node metastasis in patients with cervical cancer or endometrial cancer.
Interventions
- RADIATION fludeoxyglucose F 18
- PROCEDURE positron emission tomography
- PROCEDURE computed tomography
- PROCEDURE magnetic resonance imaging
- DRUG ferumoxtran-10
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 384 participants |
| Start Date | 2007-09 |
| Est. Completion | 2016-07-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00416455
The ClinicalTrials.gov registry entry for NCT00416455 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 384 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which fludeoxyglucose F 18 is the first listed.
NCT00416455 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00416455 about?
NCT00416455 is a clinical study titled "Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer". This phase I/II trial is studying how well fludeoxyglucose F 18 PET scan, CT scan, and ferumoxtran-10 MRI scan finds lymph node metastasis before undergoing chemotherapy and radiation therapy in patients with locally advanced cervical cancer or high-risk endometrial cancer. Diagnostic procedures, su...
What is the current status of trial NCT00416455?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 384 participants. The study started on 2007-09. Estimated completion is 2016-07-16.
What interventions are being tested in trial NCT00416455?
The interventions under investigation include: fludeoxyglucose F 18 (RADIATION), positron emission tomography (PROCEDURE), computed tomography (PROCEDURE), magnetic resonance imaging (PROCEDURE), ferumoxtran-10 (DRUG).
Who is sponsoring clinical trial NCT00416455?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.